Swiss National Bank
AMRI

Swiss National Bank’s Albany Molecular Research Inc AMRI Stock Holding History

Swiss National Bank’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-45,900
Closed -$996K – 2542
2017
Q2 		$996K Hold
45,900
– – ﹤0.01% 2055
2017
Q1 		$644K Buy
45,900
+2,600
+6% +$42.6K ﹤0.01% 2265
2016
Q4 		$812K Hold
43,300
– – ﹤0.01% 2162
2016
Q3 		$715K Hold
43,300
– – ﹤0.01% 2176
2016
Q2 		$582K Hold
43,300
– – ﹤0.01% 2273
2016
Q1 		$639K Buy
43,300
+8,100
+23% +$127K ﹤0.01% 2172
2015
Q4 		$699K Buy
35,200
+2,000
+6% +$38K ﹤0.01% 2067
2015
Q3 		$578K Buy
33,200
+4,500
+16% +$91.6K ﹤0.01% 2112
2015
Q2 		$580K Buy
28,700
+1,100
+4% +$21.2K ﹤0.01% 2152
2015
Q1 		$486K Hold
27,600
– – ﹤0.01% 2186
2014
Q4 		$449K Hold
27,600
– – ﹤0.01% 2238
2014
Q3 		$609K Hold
27,600
– – ﹤0.01% 1974
2014
Q2 		$555K Buy
+27,600
New +$467K ﹤0.01% 2108

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Swiss National Bank's AMRI Position: Q3 2017 in Review

Swiss National Bank sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 45,900 shares — an estimated $996K sold.

Swiss National Bank first reported a position in AMRI in Q2 2014 and held it in 13 quarters. The position peaked at $996K in Q2 2017. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Swiss National Bank reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Swiss National Bank sold 45,900 Albany Molecular Research Inc shares in Q3 2017, an estimated $996K.
  • Swiss National Bank first reported a position in Albany Molecular Research Inc in Q2 2014 and held it in 13 quarters.
  • Swiss National Bank's Albany Molecular Research Inc position peaked at $996K in Q2 2017.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Swiss National Bank's 13F filing for Q3 2017, filed 3 Nov 2017.